{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:47:16Z","timestamp":1773294436373,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T00:00:00Z","timestamp":1422921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Community Ment Health J"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s10597-015-9833-0","type":"journal-article","created":{"date-parts":[[2015,2,2]],"date-time":"2015-02-02T09:03:05Z","timestamp":1422867785000},"page":"685-694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Antipsychotic Cardiometabolic Side Effect Monitoring in a State Community Mental Health System"],"prefix":"10.1007","volume":"51","author":[{"given":"Robert O.","family":"Cotes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"de Nesnera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Orsini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"McHugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary F.","family":"Brunette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,3]]},"reference":[{"issue":"2","key":"9833_CR1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pds.2082","volume":"20","author":"GC Alexander","year":"2011","unstructured":"Alexander, G. C., Gallagher, S. A., Mascola, A., Moloney, R. M., & Stafford, R. S. (2011). Increasing off-label use of antipsychotic medications in the United States, 1995\u20132008. Pharmacoepidemiology and Drug Safety, 20(2), 177\u2013184.","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"1","key":"9833_CR2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1600-0447.2008.01203.x","volume":"118","author":"TR Barnes","year":"2008","unstructured":"Barnes, T. R., Paton, C., Hancock, E., Cavanagh, M. R., Taylor, D., Lelliott, P., & Health, U. K. P. O. f. M. (2008). Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: A quality improvement programme. Acta Psychiatrica Scandinavica, 118(1), 26\u201333.","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"9833_CR100","unstructured":"Brown, J. D., Barrett, A., Ireys, H., Caffey, E., & Hourihan, K. (2012). Evidence-based practices for Medicaid beneficiaries with schizophrenia and bipolar disorder (pp. 1\u201361). Washington, DC: Mathematica Policy Research."},{"key":"9833_CR3","doi-asserted-by":"crossref","unstructured":"Consensus development conference on antipsychotic drugs and obesity and diabetes. (2004a). Journal of Clinical Psychiatry, 65(2), 267\u2013272.","DOI":"10.4088\/JCP.v65n0219"},{"key":"9833_CR4","doi-asserted-by":"crossref","unstructured":"Consensus development conference on antipsychotic drugs and obesity and diabetes. (2004b). Obesity Research, 12(2), 362\u2013368.","DOI":"10.1038\/oby.2004.46"},{"key":"9833_CR5","doi-asserted-by":"crossref","unstructured":"Consensus development conference on antipsychotic drugs and obesity and diabetes. (2004c). Diabetes Care, 27(2), 596\u2013601.","DOI":"10.2337\/diacare.27.2.596"},{"issue":"10","key":"9833_CR6","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/JGP.0b013e3181e56cdc","volume":"18","author":"LA Copeland","year":"2010","unstructured":"Copeland, L. A., Parchman, M. L., Zeber, J. E., Lawrence, V. A., Downs, J. R., & Miller, A. L. (2010). Prediabetes assessment and follow-up in older veterans with schizophrenia. American Association for Geriatric Psychiatry, 18(10), 887\u2013896.","journal-title":"American Association for Geriatric Psychiatry"},{"issue":"16","key":"9833_CR7","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","volume":"302","author":"CU Correll","year":"2009","unstructured":"Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA, 302(16), 1765\u20131773.","journal-title":"JAMA"},{"issue":"1","key":"9833_CR8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chc.2005.08.007","volume":"15","author":"CU Correll","year":"2006","unstructured":"Correll, C. U., Penzner, J. B., Parikh, U. H., Mughal, T., Javed, T., Carbon, M., & Malhotra, A. K. (2006). Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child and Adolescent Psychiatric Clinics of North America, 15(1), 177\u2013206.","journal-title":"Child and Adolescent Psychiatric Clinics of North America"},{"issue":"5","key":"9833_CR9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/01.pra.0000435035.45308.03","volume":"19","author":"AD Dhamane","year":"2013","unstructured":"Dhamane, A. D., Martin, B. C., Brixner, D. I., Hudson, T. J., & Said, Q. (2013). Metabolic monitoring of patients prescribed second-generation antipsychotics. Journal of Psychiatric Practice, 19(5), 360\u2013374.","journal-title":"Journal of Psychiatric Practice"},{"issue":"3","key":"9833_CR10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1192\/pb.bp.108.021212","volume":"34","author":"C Gonzalez","year":"2010","unstructured":"Gonzalez, C., Ahammed, N., & Fisher, R. (2010). Improving physical health monitoring for out-patients on antipsychotic medication. The Psychiatrist Online, 34(3), 91\u201394.","journal-title":"The Psychiatrist Online"},{"issue":"3","key":"9833_CR11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1176\/appi.ajp.2008.08030383","volume":"166","author":"DW Haupt","year":"2009","unstructured":"Haupt, D. W., Rosenblatt, L. C., Kim, E., Baker, R. A., Whitehead, R., & Newcomer, J. W. (2009). Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. The American Journal of Psychiatry, 166(3), 345\u2013353.","journal-title":"The American Journal of Psychiatry"},{"issue":"3","key":"9833_CR12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1331\/JAPhA.2008.07007","volume":"48","author":"C Hsu","year":"2008","unstructured":"Hsu, C., Ried, L. D., Bengtson, M. A., Garman, P. M., McConkey, J. R., & Rahnavard, F. (2008). Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: Findings from a Veterans Affairs-based population. Journal of the American Pharmacists Association, 48(3), 393\u2013400.","journal-title":"Journal of the American Pharmacists Association"},{"key":"9833_CR13","unstructured":"IMS Institute for Health Care Informatics. (2011). The use of medicines in the United States: Review of 2010. http:\/\/www.imshealth.com\/cds\/imshealth\/Global\/Content\/Corporate\/IMS%20Health%20Institute\/Reports\/Use_of_Meds_in_the_U.S._Review_of_2010.pdf ."},{"key":"9833_CR14","doi-asserted-by":"crossref","unstructured":"Jamtvedt, G., Young, J. M., Kristoffersen, D. T., O\u2019Brien, M. A., & Oxman, A. D. (2006). Audit and feedback: Effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2, CD000259.","DOI":"10.1002\/14651858.CD000259.pub2"},{"issue":"12","key":"9833_CR15","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1185\/030079906X148616","volume":"22","author":"TA Ketter","year":"2006","unstructured":"Ketter, T. A., & Haupt, D. W. (2006). Perceptions of weight gain and bipolar pharmacotherapy: Results of a 2005 survey of physicians in clinical practice. Current Medical Research and Opinion, 22(12), 2345\u20132353.","journal-title":"Current Medical Research and Opinion"},{"issue":"6","key":"9833_CR16","first-page":"446","volume":"60","author":"AY Khan","year":"2010","unstructured":"Khan, A. Y., Shaikh, M. R., & Ablah, E. (2010). To examine the extent of compliance to the proposed monitoring protocol among practicing psychiatrists for second generation antipsychotics. JPMA. The Journal of the Pakistan Medical Association, 60(6), 446\u2013450.","journal-title":"JPMA. The Journal of the Pakistan Medical Association"},{"issue":"4","key":"9833_CR17","doi-asserted-by":"crossref","first-page":"e19298","DOI":"10.1371\/journal.pone.0019298","volume":"6","author":"SA Khatana","year":"2011","unstructured":"Khatana, S. A., Kane, J., Taveira, T. H., Bauer, M. S., & Wu, W. C. (2011). Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness. PLoS ONE, 6(4), e19298.","journal-title":"PLoS ONE"},{"issue":"1\u20133","key":"9833_CR18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jad.2007.01.006","volume":"102","author":"AM Kilbourne","year":"2007","unstructured":"Kilbourne, A. M., Post, E. P., Bauer, M. S., Zeber, J. E., Copeland, L. A., Good, C. B., & Pincus, H. A. (2007). Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. Journal of Affective Disorders, 102(1\u20133), 145\u2013151.","journal-title":"Journal of Affective Disorders"},{"issue":"4","key":"9833_CR19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10488-007-0115-1","volume":"34","author":"MM Kim","year":"2007","unstructured":"Kim, M. M., Swanson, J. W., Swartz, M. S., Bradford, D. W., Mustillo, S. A., & Elbogen, E. B. (2007). Healthcare barriers among severely mentally ill homeless adults: Evidence from the five-site health and risk study. Administration and Policy In Mental Health, 34(4), 363\u2013375.","journal-title":"Administration and Policy In Mental Health"},{"issue":"4 Suppl","key":"9833_CR20","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.5694\/j.1326-5377.2009.tb02374.x","volume":"190","author":"TJ Lambert","year":"2009","unstructured":"Lambert, T. J., & Newcomer, J. W. (2009). Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. The Medical Journal of Australia, 190(4 Suppl), S39\u2013S42.","journal-title":"The Medical Journal of Australia"},{"issue":"1","key":"9833_CR21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S003329171100105X","volume":"42","author":"AJ Mitchell","year":"2012","unstructured":"Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012). Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: Systematic review and meta-analysis of screening practices. Psychological Medicine, 42(1), 125\u2013147.","journal-title":"Psychological Medicine"},{"issue":"9","key":"9833_CR22","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1176\/appi.ps.201300317","volume":"65","author":"D Mittal","year":"2014","unstructured":"Mittal, D., Li, C., Viverito, K., Williams, J. S., Landes, R. D., Thapa, P. B., & Owen, R. (2014). Monitoring for metabolic side effects among outpatients with dementia receiving antipsychotics. Psychiatric Services (Washington, D. C.), 65(9), 1147\u20131153.","journal-title":"Psychiatric Services (Washington, D. C.)"},{"issue":"1","key":"9833_CR23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ps.201100445","volume":"64","author":"D Mittal","year":"2013","unstructured":"Mittal, D., Li, C., Williams, J. S., Viverito, K., Landes, R. D., & Owen, R. R. (2013). Monitoring veterans for metabolic side effects when prescribing antipsychotics. Psychiatric Services (Washington, D. C.), 64(1), 28\u201335.","journal-title":"Psychiatric Services (Washington, D. C.)"},{"issue":"1\u20133","key":"9833_CR24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2010.11.015","volume":"126","author":"KE Moeller","year":"2011","unstructured":"Moeller, K. E., Rigler, S. K., Mayorga, A., Nazir, N., & Shireman, T. I. (2011). Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance. Schizophrenia Research, 126(1\u20133), 117\u2013123.","journal-title":"Schizophrenia Research"},{"issue":"1","key":"9833_CR25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/JCP.0b013e31819294cb","volume":"29","author":"EH Morrato","year":"2009","unstructured":"Morrato, E. H., Cuffel, B., Newcomer, J. W., Lombardo, I., Kamat, S., & Barron, J. (2009a). Metabolic risk status and second-generation antipsychotic drug selection: A retrospective study of commercially insured patients. Journal of Clinical Psychopharmacology, 29(1), 26\u201332.","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"9833_CR26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/archgenpsychiatry.2009.179","volume":"67","author":"EH Morrato","year":"2010","unstructured":"Morrato, E. H., Druss, B., Hartung, D. M., Valuck, R. J., Allen, R., Campagna, E., & Newcomer, J. W. (2010a). Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA\/APA recommendations for second-generation antipsychotic drugs. Archives of General Psychiatry, 67(1), 17\u201324.","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"9833_CR27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/pds.2062","volume":"20","author":"EH Morrato","year":"2011","unstructured":"Morrato, E. H., Druss, B. G., Hartung, D. M., Valuck, R. J., Thomas, D., Allen, R., & Newcomer, J. W. (2011). Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users. Pharmacoepidemiology and Drug Safety, 20(1), 66\u201375.","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"2","key":"9833_CR28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4088\/JCP.v69n0219","volume":"69","author":"EH Morrato","year":"2008","unstructured":"Morrato, E. H., Newcomer, J. W., Allen, R. R., & Valuck, R. J. (2008). Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: A retrospective, population-based study of Medicaid claims data. Journal of Clinical Psychiatry, 69(2), 316\u2013322.","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"9833_CR29","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2337\/dc08-1720","volume":"32","author":"EH Morrato","year":"2009","unstructured":"Morrato, E. H., Newcomer, J. W., Kamat, S., Baser, O., Harnett, J., & Cuffel, B. (2009b). Metabolic screening after the American Diabetes Association\u2019s consensus statement on antipsychotic drugs and diabetes. Diabetes Care, 32(6), 1037\u20131042.","journal-title":"Diabetes Care"},{"issue":"4","key":"9833_CR30","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpediatrics.2010.48","volume":"164","author":"EH Morrato","year":"2010","unstructured":"Morrato, E. H., Nicol, G. E., Maahs, D., Druss, B. G., Hartung, D. M., Valuck, R. J., & Newcomer, J. W. (2010b). Metabolic screening in children receiving antipsychotic drug treatment. Archives of Pediatrics and Adolescent Medicine, 164(4), 344\u2013351.","journal-title":"Archives of Pediatrics and Adolescent Medicine"},{"issue":"4","key":"9833_CR31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4088\/PCC.v08n0405","volume":"8","author":"C Motsinger","year":"2006","unstructured":"Motsinger, C., Slack, M., Weaver, M., & Reed, M. (2006). Physician patterns of metabolic screening for patients taking atypical antipsychotics: A retrospective database study. Primary Care Companion to the Journal of Clinical Psychiatry, 8(4), 220\u2013223.","journal-title":"Primary Care Companion to the Journal of Clinical Psychiatry"},{"issue":"12","key":"9833_CR32","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/archgenpsychiatry.2012.647","volume":"69","author":"M Olfson","year":"2012","unstructured":"Olfson, M., Blanco, C., Liu, S. M., Wang, S., & Correll, C. U. (2012). National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Archives of General Psychiatry, 69(12), 1247\u20131256.","journal-title":"Archives of General Psychiatry"},{"key":"9833_CR33","doi-asserted-by":"crossref","unstructured":"Raebel, M. A., Penfold, R., McMahon, A. W., Reichman, M., Shetterly, S., Goodrich, G., et al. (2014). Adherence to guidelines for glucose assessment in starting second-generation antipsychotics. Pediatrics.","DOI":"10.1542\/peds.2014-0828"},{"issue":"5","key":"9833_CR34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/070674371205700504","volume":"57","author":"R Ronsley","year":"2012","unstructured":"Ronsley, R., Rayter, M., Smith, D., Davidson, J., & Panagiotopoulos, C. (2012). Metabolic monitoring training program implementation in the community setting was associated with improved monitoring in second-generation antipsychotic-treated children. Canadian Journal of Psychiatry, 57(5), 292\u2013299.","journal-title":"Canadian Journal of Psychiatry"},{"key":"9833_CR35","doi-asserted-by":"crossref","unstructured":"Shi, L., Ascher-Svanum, H., Chiang, Y. J., Zhao, Y., Fonseca, V., & Winstead, D. (2009). Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry, 9(Journal Article), 80.","DOI":"10.1186\/1471-244X-9-80"},{"key":"9833_CR36","unstructured":"Suppes, T., McElroy, S. L., & Hirschfeld, R. (2007). Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: A survey of 500 US psychiatrists. Psychopharmacology Bulletin, 40(2), 22\u201337; quiz 38\u201340."},{"issue":"2","key":"9833_CR37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10597-011-9472-z","volume":"49","author":"DI Velligan","year":"2013","unstructured":"Velligan, D. I., Castillo, D., Lopez, L., Manaugh, B., Davis, C., Rodriguez, J., & Miller, A. L. (2013). A case control study of the implementation of change model versus passive dissemination of practice guidelines for compliance in monitoring for metabolic syndrome. Community Mental Health Journal, 49(2), 141\u2013149.","journal-title":"Community Mental Health Journal"},{"issue":"4","key":"9833_CR38","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3371\/CSRP.5.4.4","volume":"5","author":"E Weissman","year":"2012","unstructured":"Weissman, E., Jackson, C., Schooler, N., Goetz, R., & Essock, S. (2012). Monitoring metabolic side effects when initiating treatment with second-generation antipsychotic medication. Clin Schizophr Relat Psychoses, 5(4), 201\u2013207.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"9","key":"9833_CR39","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.4088\/JCP.v67n0901","volume":"67","author":"EM Weissman","year":"2006","unstructured":"Weissman, E. M., Zhu, C. W., Schooler, N. R., Goetz, R. R., & Essock, S. M. (2006). Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics. Journal of Clinical Psychiatry, 67(9), 1323\u20131326.","journal-title":"Journal of Clinical Psychiatry"}],"container-title":["Community Mental Health Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10597-015-9833-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10597-015-9833-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10597-015-9833-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T12:18:42Z","timestamp":1566303522000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10597-015-9833-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,3]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["9833"],"URL":"https:\/\/doi.org\/10.1007\/s10597-015-9833-0","relation":{},"ISSN":["0010-3853","1573-2789"],"issn-type":[{"value":"0010-3853","type":"print"},{"value":"1573-2789","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,3]]}}}